Rudi Schmidt’s Post

Check out the two new #CTSAProgram Working Group pages added to the CCOS website! 1) Translational Science Case Studies: https://ow.ly/En4u50QIXX3 2) Harnessing Innovation and Engagement: https://ow.ly/iXBo50QIXXo

Conscience open science model is revolutionizing the drug discovery process. This model sparks collaboration between companies, researchers and academics, in contrast to the patent-driven model where scientists work alone. An open and transparent exchange of data makes the drug-discovery process faster and more affordable. #ICYMI: Conscience’s first open science competition yielded a promising discovery that could lead to better treatments for Parkinson’s Disease. Learn more: https://conscience.ca/ #LoveData24 #OpenScience

Discover how the Inventia Life Science platform replicates real human tissue structure and behavior across various disease states, offering unparalleled physiological complexity. This enables world-class research and breakthroughs—right in your lab. #3DCellbiology #Biotech #CellModels #DrugDiscovery #BiomedicalResearch

Happy to share that I've successfully completed the 'Introduction to Omics & its Role in Clinical Research' online workshop! It was an insightful journey delving into the intersection of technology and healthcare. Grateful for the opportunity to enhance my expertise in this dynamic field.❤ #Omics #ClinicalResearch #ContinuousLearning"

The Role of Genomics in Modern Healthcare Genomics is at the forefront of a new era in healthcare, where personalized medicine is becoming the norm. By understanding the genetic makeup of individuals, we can develop more targeted and effective treatments for a variety of diseases. At Genomac Holdings, we're leveraging the power of genomics to drive innovation in healthcare, from research to real-world applications. Our work is not just about advancing science; it's about making a tangible difference in people's lives. As we continue to explore the potential of genomics, we're excited to share our findings and collaborate with global stakeholders to push the boundaries of what's possible in healthcare. #Genomics #HealthcareInnovation #PersonalizedMedicine #Biotech #Innovation

If you are working in drug discovery or work with knowledge graphs in any field - check out the following webinar tomorrow from my colleague Andreas Kramer. Its titled "Leveraging the QIAGEN Knowledge Graph and Causal Embeddings for Insights into Drug Repurposing". Timing: June 18, 2024 1:00 PM - 2:30 PM US EST Andreas will cover some of the following topics in his webinar: - How to connect diverse entities and relationships using biomedical knowledge graphs. - The potential of knowledge graphs to uncover new insights from existing data. - A machine learning-based approach utilizing causal interactions from the QIAGEN Knowledge Graph. - Predicting novel drug-disease relationships and constructing networks with relevant supporting evidence. You can register for the talk here: https://lnkd.in/gD-XV9ZV Reach out if you have questions or want to talk after. #DrugDiscovery #DataScience #Webinar #QIAGEN #DrugRepurposing #LifeSciences #ResearchInnovation

Last chance to register! 👉 https://buff.ly/3XmDSEj Join us at 2pm BST for a discussion around moving compounds to IND using predictive retina models💡 #Newcells #VisionResearch #Retina #PredictiveModels

We were thrilled  to participate in and support the recent Bio3 conference 2024 🎉 . A big thank you to Bio-Innovation Greece and the core organizing committee Georgia Kokaraki PhD, PMP, Nikos Kyrpides, Georgios Pavlopoulos, Michalis Hadjithomas for inviting us and for putting together such an outstanding event, bringing together a remarkable concentration  of knowledgeable individuals and groups from industry and academia. This initiative successfully united a diverse range of professionals from bioinformatics, biotech, and pharma. Through inspiring presentations and panel discussions it sparkled valuable conversations about the challenges faced by  both in the academia and industry offering fresh perspectives. We had  a great opportunity to expand our network, deepen our expertise, and share insights from our vision and work with the community. Highlights Booth: Our team engaged with numerous professionals at our booth, discussing our technical innovations and exchanging ideas with peers from both academia and industry. Special thanks 💚 to Aigli Korfiati, Afroditi Kravari, and Nikolaos Mourdoukoutas for their valuable contribution and continuous support. Presentation: Within the 4th day devoted to "AI in Drug Development" and the session chaired by Michalis Hadjithomas we attended 👀 exciting presentations from all speakers: Stavros Papadopoulos, Yiannis Kourmpetis, PhD, and Christina Koutsoumpa, PhD, elaborating on complementary aspects such as Tile-DB and multiomics databases, AI-assisted targeted innovation/ patent strategy, and medical imaging. Vassilis Pitsikalis took the stage to present our work in the area, emphasizing the importance on integrating interdisciplinary domain knowledge to develop trustworthy and interpretable AI models.  👉 Feel free to connect with us ! We look forward to understanding the challenges the community faces and building impactful collaborations to develop  effective real-world healthcare solutions. #Bio3 #MachineLearning #Bioinformatics #Biotechnology #Deeplab #BioInnovation

We are proud to announce that CN Bio has been featured in Business Weekly newspaper's Killer 50 list for the second year running! 🎉 Their list highlights the top 50 life science companies in the UK with the most disruptive technologies. We are honored to have our innovative PhysioMimix® Organ-on-a-chip Systems recognized once again. Our incredible team is on a mission to enable our customers to do something incredible – recreate three-dimensional human organs and tissues in the laboratory to better understand human physiology, disease, and the effectiveness of new drugs. Why? To facilitate a future where drugs are discovered more quickly, brought to patients more cost-effectively, and through the use of less animal experimentation. Discover how our PhysioMimix platform, its applications, and our contract research services support this mission at https://bit.ly/3UjYwT7. #LifeSciences #Innovation #OrganOnAChip #Killer50

🥁 New preprint alert: #Benchmarking second-generation methods for cell-type #deconvolution of #transcriptomic data 👉 https://lnkd.in/diYZPWFW Second-generation #deconvolution methods can be trained with scRNA-seq data to estimate the cellular composition of bulk RNA-seq samples. This flexibility can unlock the deconvolution of any cell type, tissue, and organism, but poses major challenges to methods benchmarking. We put together a unique set of real and simulated datasets to comprehensively benchmark second-generation deconvolution tools in various scenarios, and systematically assess how deconvolution performance is affected by different sources of variation and bias. In addition, we provide the scientific community with an ecosystem of tools and resources, #omnideconv, that strongly simplifies the application, benchmarking, and optimization of deconvolution methods. 👉 omnideconv.org Great collaboration with Markus List ✨ 👏 Kudos to Alexander Dietrich and Lorenzo Merotto for leading this effort, and to all the co-authors: Konstantin P. Bernhard Eder Constantin Zackl Katharina Reinisch Edenhofer Frank Federico Marini Gregor Sturm 🙏 Many thanks to Universität Innsbruck #DiSC Austrian Science Fund FWF Oesterreichische Nationalbank Bundesministerium für Bildung und Forschung #MyeInfoBank for supporting our work We hope our study and set of tools and resources can be helpful to the scientific community 💫